Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Fabrice Duval, Barry D. Lebowitz & Jean-Paul Macher. (2006) Treatments in depression. Dialogues in Clinical Neuroscience 8:2, pages 191-206.
Read now
Read now
Articles from other publishers (27)
Jane E. Brumbaugh, Colleen T. Ball, Julia E. Crook, Cynthia J. Stoppel, William A. Carey & William V. Bobo. (2023) Poor Neonatal Adaptation After Antidepressant Exposure During the Third Trimester in a Geographically Defined Cohort. Mayo Clinic Proceedings: Innovations, Quality & Outcomes 7:2, pages 127-139.
Crossref
Crossref
Chris F Johnson, Margaret Maxwell, Brian Williams, Nadine Dougall & Stephen MacGillivray. (2022) Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis. BMJ Medicine 1:1, pages e000017.
Crossref
Crossref
Eugenia Papalexi, Andreas Galanopoulos, Dimitrios Kontis, Maria Markopoulou, Georgia Balta, Evaggelos Karavelas, Panagiotis Panagiotidis, Themistoklis Vlachos & Anders Ettrup. (2022) Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects. BMC Psychiatry 22:1.
Crossref
Crossref
Alexander Lisinski, Fredrik Hieronymus, Staffan Nilsson & Elias Eriksson. (2022) Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo. Translational Psychiatry 12:1.
Crossref
Crossref
Azmi Nasser, Roberto Gomeni, Zhao Wang, Alisa R. Kosheleff, Lanyi Xie, Lilian W. Adeojo & Stefan Schwabe. (2021) Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder. The Journal of Clinical Pharmacology 61:12, pages 1626-1637.
Crossref
Crossref
Alexander Lisinski, Fredrik Hieronymus, Elias Eriksson & Susanna M. Wallerstedt. (2021) Low SSRI dosing in clinical practice—a register‐based longitudinal study. Acta Psychiatrica Scandinavica 143:5, pages 434-443.
Crossref
Crossref
Mahmoud S. Abdallah, Esraa M. Mosalam, Abdel-Aziz A. Zidan, Khaled S. Elattar, Shimaa A. Zaki, Ahmed N. Ramadan & Abla M. Ebeid. (2020) RETRACTED ARTICLE: The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. Neurotherapeutics 17:4, pages 1897-1906.
Crossref
Crossref
Xinyu Zhou, Teng Teng, Yuqing Zhang, Cinzia Del Giovane, Toshi A Furukawa, John R Weisz, Xuemei Li, Pim Cuijpers, David Coghill, Yajie Xiang, Sarah E Hetrick, Stefan Leucht, Mengchang Qin, Jürgen Barth, Arun V Ravindran, Lining Yang, John Curry, Li Fan, Susan G Silva, Andrea Cipriani & Peng Xie. (2020) Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. The Lancet Psychiatry 7:7, pages 581-601.
Crossref
Crossref
Qingqing Cheng, Jihan Huang, Ling Xu, Yunfei Li, Huafang Li, Yifeng Shen, Qingshan Zheng & Lujin Li. (2020) Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression. International Journal of Neuropsychopharmacology 23:2, pages 76-87.
Crossref
Crossref
Ching-Hua Lin, Li-Shiu Chou, Shu-Hui Tang & Chun-Jen Huang. (2019) Do baseline WAIS-III subtests predict treatment outcomes for depressed inpatients receiving fluoxetine?. Psychiatry Research 271, pages 279-285.
Crossref
Crossref
Ching-Hua Lin, Chun-Jen Huang & Cheng-Chung Chen. (2018) ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis. International Journal of Neuropsychopharmacology 21:1, pages 63-72.
Crossref
Crossref
Gui-Feng Tong, Nan Qin & Li-Wei Sun. (2017) Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery. Saudi Pharmaceutical Journal 25:6, pages 844-851.
Crossref
Crossref
Daniel J. Safer. (2016) Raising the Minimum Effective Dose of Serotonin Reuptake Inhibitor Antidepressants. Journal of Clinical Psychopharmacology 36:5, pages 483-491.
Crossref
Crossref
Roy H. Perlis. (2016) Abandoning personalization to get to precision in the pharmacotherapy of depression. World Psychiatry 15:3, pages 228-235.
Crossref
Crossref
F Hieronymus, S Nilsson & E Eriksson. (2016) A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Translational Psychiatry 6:6, pages e834-e834.
Crossref
Crossref
Aarthi Manoharan, Ravi Philip Rajkumar, Deepak Gopal Shewade, Rajan Sundaram, Avin Muthuramalingam & Abialbon Paul. (2016) Evaluation of interleukin‐6 and serotonin as biomarkers to predict response to fluoxetine. Human Psychopharmacology: Clinical and Experimental 31:3, pages 178-184.
Crossref
Crossref
Teruhiko Higuchi, Kunitoshi Kamijima, Kazuyuki Nakagome, Rio Itamura, Yuko Asami, Kazuhiko Kuribayashi & Takayuki Imaeda. (2016) A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan. International Clinical Psychopharmacology 31:1, pages 8-19.
Crossref
Crossref
Roy H. Perlis. 2016. Genomics, Circuits, and Pathways in Clinical Neuropsychiatry. Genomics, Circuits, and Pathways in Clinical Neuropsychiatry
727
747
.
Huey-Shyan Lin, Fu-Chiang Wang & Ching-Hua Lin. (2015) Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine. Journal of Clinical Psychopharmacology 35:6, pages 661-666.
Crossref
Crossref
Ching-Hua Lin, Li-Shiu Chou, Ming-Chao Chen & Cheng-Chung Chen. (2015) The relationship between symptom relief and functional improvement during acute fluoxetine treatment for patients with major depressive disorder. Journal of Affective Disorders 182, pages 115-120.
Crossref
Crossref
M. Kellner, T. Porseryd, I. Porsch-Hällström, S.H. Hansen & K.H. Olsén. (2015) Environmentally relevant concentrations of citalopram partially inhibit feeding in the three-spine stickleback (Gasterosteus aculeatus). Aquatic Toxicology 158, pages 165-170.
Crossref
Crossref
Sidney H. Kennedy, Alla Avedisova, Natalia Giménez-Montesinos, Carole Belaïdi & Bodinat Christian de. (2014) A placebo-controlled study of three agomelatine dose regimens (10mg, 25mg, 25–50mg) in patients with major depressive disorder. European Neuropsychopharmacology 24:4, pages 553-563.
Crossref
Crossref
Roy H Perlis. (2014) Pharmacogenomic Testing and Personalized Treatment of Depression. Clinical Chemistry 60:1, pages 53-59.
Crossref
Crossref
Ibrahim A Abdel-HamidKarl-Erik Andersson. (2009) Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications. Pharmacogenomics 10:10, pages 1625-1644.
Crossref
Crossref
David G.S. Perahia, Yili Lu Pritchett, Daniel K. Kajdasz, Michael Bauer, Rakesh Jain, James M. Russell, Daniel J. Walker, Kimberly A. Spencer, Debbie M. Froud, Joel Raskin & Michael E. Thase. (2008) A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Journal of Psychiatric Research 42:1, pages 22-34.
Crossref
Crossref
Yili L. Pritchett, Martin D. Marciniak, Patricia K. Corey-Lisle, Richard A. Berzon, Durisala Desaiah & Michael J. Detke. (2007) Use of effect size to determine optimal dose of duloxetine in major depressive disorder. Journal of Psychiatric Research 41:3-4, pages 311-318.
Crossref
Crossref
David A. Brent & Boris Birmaher. (2006) Treatment-Resistant Depression in Adolescents: Recognition and Management. Child and Adolescent Psychiatric Clinics of North America 15:4, pages 1015-1034.
Crossref
Crossref